Federally-Listed PSOs

Below is a list of PSOs that are currently listed by AHRQ. A health care provider can only obtain the confidentiality and privilege protections of the Patient Safety Act by working with a Federally-listed PSO.

Use the categories on the left to filter the list of PSOs or search a PSO name.

Note: AHRQ updates the PSO information contained within the directories weekly, as needed; changes are made when there are newly listed PSOs and/or when existing information requires revision. Changes that would otherwise be effective on a weekend day or holiday will be effective on the next business day. Information contained in the directories is based on attestations that the PSOs provide. To update PSO contact information, please use the Change of Listing Information form; to update profile information, please go to the PSO PPC Web site.

There are 87 total PSOs listed by AHRQ.

PLEASE NOTE: To search for a PSO by State, use the 2 letter state abbreviation. Example: Kansas = KS

Ascension Healthcare Patient Safety Organization - P0111
Component of Parent Org(s):
  • Ascension
Effective Date and Time of Initial Listing: May 11, 2011 12:01 AM ET
PSO Mailing Address: 4600 Edmundson Road, St. Louis, MO 63134
PSO Phone Number: 314-733-8164
Point of Contact: Ruth Eaker
Point of Contact Phone: 314-733-8164
Point of Contact Email: Ruth.Eaker@ascension.org (link is external)
Two Bona Fide Contract Requirement: Next attestation period is 05/11/2021 through 05/10/2023
Disclosures & Finding: None
Subject to FDA-Regulated Reporting Entity Guidance: Yes
Strategic Radiology Patient Safety Organization LLC - P0144
Component of Parent Org(s):
  • Strategic Radiology LLC
Effective Date and Time of Initial Listing: June 19, 2013 12:01 AM ET
PSO Mailing Address: PO Box 1418, Palmetto, FL 34221
PSO Phone Number: (810) 210-9885
Point of Contact: Lisa A. Mead MS, CPHQ
Point of Contact Phone: (480) 794-0483
Point of Contact Email: lmead@strategicradiology.org (link is external)
Two Bona Fide Contract Requirement: Next attestation period is 06/19/2019 through 06/18/2021
Disclosures & Finding: None
Subject to FDA-Regulated Reporting Entity Guidance: No